ORMP (STOCKS)
Oramed Pharmaceuticals Inc.
$3.722800
+0.192800 (+5.46%)
Prev close: $3.530000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Nadav Kidron
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $152.48M
- Employees
- 13
- P/E (TTM)
- 2.35
- P/B (TTM)
- 0.69
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.24 | $0.00 | +0.2447 | +0.00% |
|
Sep 2025 (Q3)
|
$1.12 | $-0.04 | +1.1608 | +2,845.10% |
|
Jun 2025 (Q2)
|
$0.31 | $-0.04 | +0.3508 | +859.80% |
|
Mar 2025 (Q1)
|
$-0.19 | $-0.01 | -0.1798 | -1,762.75% |
Financial Statements
| Revenues | $2.00M |
| Benefits Costs and Expenses | -$73.32M |
| Cost Of Revenue | $1.99M |
| Costs And Expenses | -$73.32M |
| Gross Profit | $13.00K |
| Nonoperating Income/Loss | $89.45M |
| Operating Expenses | $15.10M |
| Research and Development | $6.38M |
| Other Operating Expenses | $8.72M |
| Operating Income/Loss | -$15.09M |
| Income/Loss From Continuing Operations After Tax | $64.02M |
| Income/Loss From Continuing Operations Before Tax | $75.32M |
| Income Tax Expense/Benefit | $11.31M |
| Income Tax Expense/Benefit, Current | $3.57M |
| Income Tax Expense/Benefit, Deferred | $7.91M |
| Net Income/Loss | $64.02M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$34.00K |
| Net Income/Loss Attributable To Parent | $64.05M |
| Net Income/Loss Available To Common Stockholders, Basic | $63.24M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $808.00K |
| Preferred Stock Dividends And Other Adjustments | $808.00K |
| Basic Earnings Per Share | $1.53 |
| Diluted Earnings Per Share | $1.50 |
| Basic Average Shares | 41,402,997 |
| Diluted Average Shares | 42,418,644 |
| Common Stock Dividends | $0.25 |
| Assets | $230.86M |
| Current Assets | $133.27M |
| Prepaid Expenses | $449.00K |
| Other Current Assets | $132.82M |
| Noncurrent Assets | $97.59M |
| Fixed Assets | $586.00K |
| Other Non-current Assets | $97.01M |
| Liabilities | $31.12M |
| Current Liabilities | $19.09M |
| Accounts Payable | $443.00K |
| Wages | $755.00K |
| Other Current Liabilities | $17.89M |
| Noncurrent Liabilities | $12.03M |
| Equity | $199.74M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $199.74M |
| Liabilities And Equity | $230.86M |
| Net Cash Flow From Operating Activities | -$9.15M |
| Net Cash Flow From Operating Activities, Continuing | -$9.15M |
| Net Cash Flow From Investing Activities | $5.44M |
| Net Cash Flow From Investing Activities, Continuing | $5.44M |
| Net Cash Flow From Financing Activities | -$4.74M |
| Net Cash Flow From Financing Activities, Continuing | -$4.74M |
| Exchange Gains/Losses | -$30.00K |
| Net Cash Flow | -$8.47M |
| Net Cash Flow, Continuing | -$8.44M |
| Comprehensive Income/Loss | $64.02M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $64.02M |
| Other Comprehensive Income/Loss | $0.00 |